Neuphoria Therapeutics Inc.(NEUP)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

Neuphoria Therapeutics Inc. (NEUP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NEUP at 31.6/100 on a 32-signal composite quality model, placing it at rank #2,448 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of NEUP by reported 13-F value include Lynx1 Capital Management, AdvisorShares Investments, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NEUP trades on the Nasdaq exchange and files with the SEC under CIK 1191070. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NEUP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neuphoria Therapeutics Inc. directly from SEC EDGAR.